Growth Metrics

RemSleep Holdings (RMSL) Amortization of Deferred Charges (2024 - 2025)

RemSleep Holdings recorded quarterly Amortization of Deferred Charges of -$43275.0 in Q4 2025, up 85.28% quarter-over-quarter from -$293958.0 in Q3 2025, and down 220.98% year-over-year from $35770.0 in Q4 2024.

RemSleep Holdings' Amortization of Deferred Charges history runs 2 years deep, the most recent figure standing at -$43275.0 for Q4 2025.

  • In Q4 2025, Amortization of Deferred Charges fell 220.98% year-over-year to -$43275.0; the TTM figure through Dec 2025 stood at $27701.0 (down 72.34% YoY), while the FY2025 annual figure was $27701.0, down 72.34% from the prior year.
  • Amortization of Deferred Charges came in at -$43275.0 for Q4 2025 at RemSleep Holdings, up from -$293958.0 in the prior quarter.
  • In the past five years, Amortization of Deferred Charges ranged from a high of $219724.0 in Q1 2025 to a low of -$293958.0 in Q3 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Abbott Laboratories 152.82 Bn 146.17 Bn 6.27 Bn
2 Stryker 115.07 Bn 112.19 Bn 3.81 Bn
3 Medtronic 95.25 Bn 87.08 Bn 5.76 Bn
4 Boston Scientific 71.38 Bn 70.17 Bn 3.61 Bn
5 Edwards Lifesciences 51.08 Bn 47.41 Bn 1.29 Bn
6 Koninklijke Philips 29.38 Bn 26.07 Bn 2.07 Bn
7 Dexcom 28.84 Bn 27.72 Bn 750.30 Mn
8 GE HealthCare Technologies 28.56 Bn 26.49 Bn 1.98 Bn
9 Steris 20.71 Bn 20.30 Bn 697.10 Mn
10 RemSleep Holdings - - -7,636.00

Historic Data

Download Data 🔒
DateValue
Dec 31, 2025 -43,275.00
Dec 31, 2025 -43,275.00
Sep 30, 2025 -293,958.00
Sep 30, 2025 -293,958.00
Jun 30, 2025 145,210.00
Jun 30, 2025 145,210.00
Mar 31, 2025 219,724.00
Mar 31, 2025 219,724.00
Dec 31, 2024 35,770.00
Dec 31, 2024 35,770.00
Jun 30, 2024 -29,719.00
Jun 30, 2024 -29,719.00
Mar 31, 2024 94,111.00
Mar 31, 2024 94,111.00